Renovia, founded in 2016, is dedicated to developing prescription digital therapeutics aimed at improving the lives of women suffering from pelvic floor disorders. The company's core mission is to enhance women's pelvic health through innovative healthcare software solutions. Renovia's flagship product, the Leva System, assists with pelvic floor muscle training (PFMT), a first-line treatment for urinary incontinence. The company focuses on the healthcare market, specifically targeting women's health issues that are often underrepresented and undertreated.

Notable figures associated with Renovia include co-founder and CEO Marc Beer, who has extensive experience in the biotech and pharmaceutical industries. The company has attracted significant investment from prominent venture capital firms such as Perceptive Advisors and Ascension Ventures. Key achievements include securing FDA clearance for the Leva System and publishing impactful studies in reputable journals like the International Urogynecology Journal. Renovia's work has made a substantial impact by providing effective, non-invasive treatment options for women worldwide, particularly in regions where healthcare resources are limited.